2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Einstein D, Catalano P, Hammers H, Regan M. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal For ImmunoTherapy Of Cancer 2024, 12: e008293. PMID: 38604810, PMCID: PMC11015345, DOI: 10.1136/jitc-2023-008293.Peer-Reviewed Original ResearchConceptsTreatment-free survivalInternational Metastatic RCC Database ConsortiumFavorable-risk patientsNivolumab monotherapyPhase II study of nivolumabCessation of immunotherapyFavorable-risk diseaseProtocol therapy cessationStudy of nivolumabSystemic therapy initiationTreatment naive patientsPhase II studyRenal cell carcinomaKaplan-Meier curvesActive treatment approachPartitioned survival analysisCheckMate 067Stable diseaseProtocol therapyAdvanced melanomaTherapy initiationTreatment-freeCell carcinomaClear-cellProtocol treatment
2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy
Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy. BJU International 2010, 106: 772-778. PMID: 20230385, DOI: 10.1111/j.1464-410x.2010.09218.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, NeoplasmAntineoplastic AgentsBenzenesulfonatesCarbonic Anhydrase IXCarbonic AnhydrasesCarcinoma, Renal CellEpidemiologic MethodsFemaleHumansImmunohistochemistryIndolesKidney NeoplasmsMaleMiddle AgedNeoplasm ProteinsNiacinamidePhenylurea CompoundsPrognosisPyridinesPyrrolesSorafenibSunitinibTreatment OutcomeVascular Endothelial Growth Factor AConceptsMetastatic clear-cell renal cell carcinomaVEGF-targeted therapyCarbonic anhydrase IXClear-cell renal cell carcinomaClear-cell componentRenal cell carcinomaTumor shrinkageCell carcinomaClear-cellTreated with vascular endothelial growth factor (VEGF)-targeted therapyVascular endothelial growth factor (VEGF)-targeted therapyVascular endothelial growth factor-targeted therapyAssociated with greater tumor shrinkageCarbonic anhydrase IX expressionResponse to sorafenib treatmentSunitinib-treated patientsResponse to sunitinibSorafenib-treated patientsPredictors of outcomeSunitinib treatmentSorafenib treatmentPrimary endpointPredictive biomarkersPrognostic valueCAIX expression
1995
Report of Eight Cases and Review of the Literature
Hasserjian R, Klimstra D, Rosai J. Report of Eight Cases and Review of the Literature. The American Journal Of Surgical Pathology 1995, 19: 835-841. PMID: 7793482, DOI: 10.1097/00000478-199507000-00012.Peer-Reviewed Original ResearchConceptsClear-cell featuresThymic carcinomaClear-cellCases of thymic carcinomaHigh-grade thymic carcinomasMetastatic clear-cell carcinomaSheet-like growth patternHigh-molecular-weight keratinPrimary thymic carcinomaDead of diseaseClear-cell carcinomaEpithelial membrane antigenAggressive clinical behaviorClear-cell neoplasmsMediastinal seminomaPlacental alkaline phosphataseParathyroid carcinomaPersistent diseaseMembrane antigenClinical behaviorTumor cellsDifferential diagnosisFollow-upCarcinomaNuclear features
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply